

Anti-Human I-309
Developed in Goat
IgG Fraction of Antiserum

Product No. I 7391

Anti-Human I-309 is developed in goat using recombinant human I-309, expressed in *E. coli*, as immunogen. The product is purified by Protein G affinity chromatography. Goat Anti-Human I-309 is provided lyophilized from phosphate buffered saline, to which no preservatives are added.

Description

I-309 is a member of the C-C, or β chemokine class. Other chemokines in this group include MIP-1 α , MIP-1 β , RANTES, MCP-1/2/3/4, mouse JE, mouse MARC, eotaxin, HCC-1 and C10. These chemokines act primarily as chemoattractants and activate monocytes, dendritic cells, T lymphocytes, natural killer cells, B lymphocytes, basophils and eosinophils. I-309 was originally identified by subtractive hybridization as a transcript that was present in a γ/δ T cell line but not in EBV-transformed B cells. I-309 is a chemoattractant for monocytes, but not for neutrophils. IP-10 is an approximately 8.5 kD polypeptide of 73 amino acids. The precursor form of human I-309 consists of 96 amino acids. To generate the mature I-309, the precursor cleaves its hydrophobic signal peptide. Human I-309 is thought to be a homologue of the mouse TCA3, and shows 42% amino acid homology to mouse TCA3.

Performance

Anti-Human I-309 may be used in immunoblotting and ELISA. By ELISA, the antibody shows no cross-reactivity with other cytokines tested.*

* rhANG, rhAR, rh β -Cellulin, rh β -NGF, rmC10, rhCNTF, rrCNTF, rhEGF, rhENA-78, rhEPO, rhFGFa, rhFGFb, rhFGF-3, rhFGF-4, rhFGF-5, rhFGF-6, rhFGF-7, rhG-CSF, rhGDNF, rhGM-CSF R α , rmGM-CSF, rhGRO α , rhGRO β , rhGRO γ , rhHB-EGF, rhHGF, rhIFN- γ , rhIGF-I, rhIGF-I RI, rhIGF-II, rhIL-1 α , rhIL-1 RI, rhIL-1 RII, rhIL-1 α , rhIL-1 β , rhIL-1 ra, rhIL-2, rhIL-2 sR α , rhIL-2 sR β , rhIL-3, rhIL-3 sR α , rhIL-3, rhIL-4, rhIL-4 sR, rhIL-4, rhIL-5, rhIL-5 sR α , rhIL-5 sR β , rhIL-5, rhIL-6, rhIL-6 sR, rhIL-6, rhIL-7, rhIL-7 R, rhIL-7, rhIL-8, rhIL-9, rhIL-9, rhIL-10, rhIL-10, rhIL-11, rhIL-12, rhIL-13, rhIL-13, rhIP-10, rhJE, rhLIF, rhLIF R, rhLIF, rhM-CSF, rhM-CSF, rhMCP-1, rhMCP-1 R, rhMidkine, rhMIP-1 α , rhMIP-1 α , rhMIP-1 β , rhMIP-1 β , rhNT-4, rhOSM, rhPD-ECGF, hPDGF, pPDGF, rhPDGF-AA, rhPDGF-AB, rhPDGF-BB, rhPIGF, rhPTN, rhRANTES, rhSCF, rhSCF, rhsgp130, rhSLPI, hTfR, rhTGF- α , rhTGF- β 1, rhTGF- β 2, rhTGF- β 3, raTGF- β 5, rhLAP (TGF- β 1), rhLatent TGF- β 1, rhTGF- β sRII, rhTGF- β sRIII, rhTNF- α , rhTNF- α , rhTNF- β , rhTNF RI, rhTNF RII, rhVEGF.

Product Information

Mass/vial: 1 mg
 Immunogen: Recombinant, Human I-309
 Host Animal: Goat
 Formulation: Lyophilized from PBS without additives.
 Endotoxin: <10 ng/vial by LAL method
 Direct ELISA: 0.5 - 1 μ g/ml antibody detects <0.3 ng/well of recombinant, human I-309.
 Indirect Immunoblotting:
 1 - 2 μ g/ml antibody detects 20 and 5 ng recombinant, human I-309/lane under reducing and non-reducing conditions, respectively.
 Sterility: 0.2 μ m-filtered, aseptic fill

Reconstitution and Use

To one vial of lyophilized powder, add 1 ml of 0.2 μ m-filtered PBS to produce a 1 mg/ml stock solution of Anti-Human I-309. If aseptic technique is used, no further filtration should be needed for use in cell culture environments.

Storage

Prior to reconstitution, store at -20°C. Reconstituted product may be stored at 2-8°C for up to one month. For prolonged storage, freeze in working aliquots at -20°C. Avoid repeated freezing and thawing.

References

1. Miller, M.D., and Krangel, M.S., Proc. Natl. Acad. Sci. USA, **89**, 2950 (1992).
2. Miller, M.D., et al., J. Immunol., **145**, 2737 (1990).

Sigma warrants that its products conform to the information contained in this and other Sigma publications. Purchaser must determine the suitability of the products for its particular use. See reverse side of invoice or packing slip for additional terms and conditions of sale. Issued 08/97.